GlassScriptPhysician profile
Joseph W Laya
NPI 1255307724
$1,833.92
in general payments reported to CMS, 2019-2025
11 companies · $693 in 2025
The $693 reported for 2025 was more than what 90% of Low Vision Rehabilitation providers received nationally (typical 2025 total: $150).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $121 · 2021: $32.50 · 2022: $30.00 · 2023: $378 · 2024: $579 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,650.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,650.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $857.73 | 2023-2025 | Precision 1, Precision7, Rocklatan |
| Biotissue Holdings INC. | $379.67 | 2023-2025 | |
| Lombart Brothers, INC. | $133.45 | 2021-2025 | Opd-III |
| Abbvie INC. | $117.53 | 2024 | |
| Sun Pharmaceutical Industries INC. | $103.71 | 2020 | |
| Glaukos Corporation | $97.65 | 2025 | Idosetr |
| Amgen INC. | $47.76 | 2024-2025 | Tepezza |
| Tarsus Pharmaceuticals, INC. | $39.02 | 2025 | Xdemvy |
| Dompe US, INC. | $24.59 | 2025 | Oxervate |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Astellas Pharma US INC | $15.57 | 2023 | Izervay |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Laya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.